Sivieri S, Ferrarini A M, Gallo P
Department of Neurological Sciences, University of Padua, Italy.
Mult Scler. 1998 Feb;4(1):7-11. doi: 10.1177/135245859800400103.
The presence of interleukin-2 (IL-2) and soluble IL-2 receptors (sIL-2R) in the serum and cerebrospinal fluid (CSF) of patients suffering from multiple sclerosis (MS) has been extensively investigated. These studies, however, have produced conflicting results. The only significant finding concerns the frequent detection of increased sIL-2R levels in the serum in patients with relapsing-remitting MS (RRMS), especially after a short interval of time from the last relapse. Whether this finding can be used for clinical purposes requires further investigation. A standardization of the ELISA methods used to detect cytokines in biological fluids is urgently needed. Increased serum and/or CSF levels of IL-2 and sIL-2R strongly confirm a CD4+ Th1 activation.
多发性硬化症(MS)患者血清和脑脊液(CSF)中白细胞介素-2(IL-2)和可溶性IL-2受体(sIL-2R)的存在情况已得到广泛研究。然而,这些研究结果相互矛盾。唯一显著的发现是,复发缓解型多发性硬化症(RRMS)患者血清中sIL-2R水平经常检测到升高,尤其是在距上次复发短时间后。这一发现能否用于临床目的尚需进一步研究。迫切需要对用于检测生物体液中细胞因子的ELISA方法进行标准化。血清和/或脑脊液中IL-2和sIL-2R水平升高有力地证实了CD4 + Th1激活。